An Overview on the Sequential Treatment of Pancreatic Neuroendocrine Tumors (pNETs)

Patients suffering from pancreatic neuroendocrine tumors (pNETs) are now candidates to receive novel approved drugs that have demonstrated benefit in disease control rate and delay the time taken for tumor progression in Phase III clinical trials; for example, sunitinib, everolimus and lanreotide. T...

Descripción completa

Detalles Bibliográficos
Autores principales: Alonso-Gordoa, Teresa, Díez, Juan José, Molina, Javier, Reguera, Pablo, Martínez-Sáez, Olga, Grande, Enrique
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2015
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4837935/
https://www.ncbi.nlm.nih.gov/pubmed/27182476
http://dx.doi.org/10.1007/s40487-015-0007-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4837935/
https://www.ncbi.nlm.nih.gov/pubmed/27182476
http://dx.doi.org/10.1007/s40487-015-0007-6

Ejemplares similares